Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIABLE: Stapuldencel in mCRPC
NCT02111577Phase 3Completed
- Sponsor
- SOTIO Biotech
- Start
- May 2014
- Primary completion
- Jan 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 22
01
Overview
A Phase 3 trial of stapuldencel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOTIO Biotech. Started May 2014; status: completed.
02
Drugs
stapuldencel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02111577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111577.